The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

EMBO Journal

Volumn 22, Issue 13, 2003, Pages 3411-3420

  Krämer, Oliver H ^a   Zhu, Ping ^b   Ostendorff, Heather P ^c   Golebiewski, Martin ^b   Tiefenbach, Jens ^a   Peters, Marvin A ^c   Brill, Boris ^a   Groner, Bernd ^a   Bach, Ingolf ^c   Heinzel, Thorsten ^a   Göttlicher, Martin ^b,d  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

HDAC inhibitor; HDAC2; Histone deacetylase; Proteasomal degradation; Valproic acid

Indexed keywords

E2 UBIQUITIN CONJUGASE UBC8; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; PROTEASOME; TRICHOSTATIN A; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; CATALYSIS; CATALYST; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE REPLICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALS; BASE SEQUENCE; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; DNA PRIMERS; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HYDROLYSIS; HYDROXAMIC ACIDS; MICE; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN; VALPROIC ACID;

EID: 0037925520     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/cdg315     Document Type: Article

References (41)

1. Alland, L., Muhle, R., Hou, H., Jr, Potes, J., Chin, L., Schreiber-Agus, N. and DePinho, R.A. (1997) Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature, 387, 49-55.
2. Bach, I. et al. (1999) RLIM inhibits functional activity of LIM homeodomain transcription factors via recruitment of the histone deacetylase complex. Nat. Genet., 22, 394-399.
3. Carrano, A.C., Eytan, E., Hershko, A. and Pagano, M. (1999) SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol., 1, 193-199.
4. David, G., Neptune, M.A. and DePinho, R.A. (2002) SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. J. Biol. Chem., 277, 23658-23663.
5. Driever, P.H., Knüpfer, M.M., Cinatl, J. and Wolff, J.E. (1999) Valproic acid for the treatment of pediatric malignant glioma. Klin. Pädiatr., 211, 323-328.
6. Gelmetti, V., Zhang, J., Fanelli, M., Minucci, S., Pelicci, P.G. and Lazar, M.A. (1998) Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell Biol., 18, 7185-7191.
7. Glass, C.K. and Rosenfeld, M.G. (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev., 14, 121-141.
8. Glickman, M.H. and Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev., 82, 373-428.
9. Göttlicher, M. et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J., 20, 6969-6978.
10. Gray, S.G. and Ekström, T.J. (2001) The human histone deacetylase family. Exp. Cell Res., 262, 75-83.
11. Grignani, F. et al. (1998) Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature, 391, 815-818.
12. Guidez, F., Ivins, S., Zhu, J., Söderström, M., Waxman, S. and Zelent, A. (1998) Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood. 91, 2634-2642.
13. He, L.Z., Guidez, F., Tribioli, C., Peruzzi, D., Ruthardt, M., Zelent, A. and Pandolfi, P.P. (1998) Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat. Genet., 18, 126-135.
14. Heinzel, T. et al. (1997) A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature, 387, 43-48.
15. Hicke, L. (2001) Protein regulation by monoubiquitin. Nat. Rev. Mol. Cell Biol., 2, 195-201.
16. Hildebrand, D., Tiefenbach, J., Heinzel, T., Grez, M. and Maurer, A.B. (2001) Multiple regions of ETO cooperate in transcriptional repression. J. Biol. Chem., 276, 9889-9895.
17. Huang, E.Y., Zhang, J., Miska, E.A., Guenther, M.G., Kouzarides, T. and Lazar, M.A. (2000) Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev., 14, 45-54.
18. Kao, H.Y., Downes, M., Ordentlich, P. and Evans, R.M. (2000) Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev., 14, 55-66.
19. Kirsh, O. et al. (2002) The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J., 21, 2682-2691.
20. Kouzarides, T. (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO J., 19, 1176-1179.
21. Krämer, O.H., Göttlicher, M. and Heinzel, T. (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab., 12, 294-300.
22. Lagger, G. et al. (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J., 21, 2672-2681.
23. Laherty, C.D., Yang, W.M., Sun, J.M., Davie, J.R., Seto, E. and Eisenman, R.N. (1997) Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell, 89, 349-356.
24. Lin, R.J., Nagy, L., Inoue, S., Shao, W., Miller, W.H., Jr. and Evans, R.M. (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature, 391, 811-814.
25. Lutterbach, B. et al. (1998) ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol. Cell. Biol., 18, 7176-7184.
26. Marks, P.A., Richon, V.M., Breslow, R. and Rifkind, R.A. (2001) Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol., 13, 477-483.
27. Maurer, A.B., Wichmann, C., Gross, A., Kunkel, H., Heinzel, T., Ruthardt, M., Groner, B. and Grez, M. (2002) The Stat5-RARα fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood, 99, 2647-2652.
28. McKinsey, T.A., Zhang, C.L., Lu, J. and Olson, E.N. (2000) Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature, 408, 106-111.
29. Melnick, A. and Licht, J.D. (2002) Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol., 9, 322-332.
30. Nagy, L., Kao, H.Y., Chakravarti, D., Lin, R.J., Hassig, C.A., Ayer, D.E., Schreiber, S.L. and Evans, R.M. (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3A and histone deacetylase. Cell, 89, 373-380.
31. Ostendorff, H.P., Peirano, R.I., Peters, M.A., Schlüter, A., Bossenz, M., Scheffner, M. and Bach, I. (2002) Ubiquitination-dependent cofactor exchange on LIM homeodomain transcription factors. Nature, 416, 99-103.
32. Phiel, C.J., Zhang, F., Huang, E.Y., Guenther, M.G., Lazar, M.A. and Klein, P.S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen. J. Biol. Chem., 276, 36734-36741.
33. Regan, C.M. (1985) Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin. Brain Res., 347, 394-398.
34. Strahl, B.D. and Allis, C.D. (2000) The language of covalent histone modifications. Nature, 403, 41-45.
35. van der Vlag, J. and Otte, A.P. (1999) Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat. Genet., 23, 474-478.
36. Varambally, S. et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419, 624-629.
37. Wang, J., Hoshino, T., Redner, R.L., Kajigaya, S. and Liu, J.M. (1998) ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl Acad. Sci. USA, 95, 10860-10865.
38. Warrell, R.P., He, L.Z., Richon, V., Calleja, E. and Pandolfi, P.P. (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl Cancer Inst., 90, 1621-1625.
39. Yang, W.M., Yao, Y.L., Sun, J.M., Davie, J.R. and Seto, E. (1997) Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem., 272, 28001-28007.
40. Zhang, C.L., McKinsey, T.A., Chang, S., Antos, C.L., Hill, J.A. and Olson, E.N. (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell, 110, 479-488.
41. Zhou, Q., Melkoumian, Z.K., Lucktong, A., Moniwa, M., Davie, J.R. and Strobl, J.S. (2000) Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J. Biol. Chem., 275, 35256-35263.